Precision BioSciences Earnings Call Transcripts
Fiscal Year 2026
-
ARCUS gene editing platform underpins two lead programs: PBGENE-HBV for hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy. Early clinical and preclinical data show promising efficacy and safety, with key data readouts expected in 2026 and a strong cash runway through 2028.
-
The company highlighted progress in its ARCUS-based gene editing programs for DMD and HBV, with IND clearance for DMD and plans to treat 3-5 patients in 2024. Early data from both programs show promising efficacy and safety, with further clinical results expected by year-end.
Fiscal Year 2025
-
Two in-vivo gene editing programs are advancing: PBGENE-HBV for hepatitis B shows promising dose-dependent antiviral activity and sustained S antigen reduction, while PBGENE-DMD targets a large DMD patient segment with preclinical success. Financing supports milestones through 2028, with key data readouts expected in 2026.
-
PBGENE-HBV demonstrated dose-dependent antiviral activity and a strong safety profile in phase I, with clinical biopsy confirming on-target gene editing and S antigen reduction. The program is advancing globally, supported by new funding, while the DMD program is on track for clinical entry in 2026.
-
Genome editing is advancing with new platforms like ARCUS and engineered recombinases, enabling precise and durable gene insertion for a range of diseases. Clinical data show promise in severe pediatric and liver indications, with regulatory and investor support growing as the field moves toward broader applications and commercial viability.
-
The conference showcased the ARCUS gene editing platform, emphasizing its unique features and potential to achieve a complete cure for HBV by targeting cccDNA. Early clinical data show strong safety and promising antiviral activity, with further results and expanded studies expected soon.
-
ARCUS offers a compact, efficient gene-editing platform enabling all-in-one AAV delivery for DMD, targeting the exon 45-55 hotspot and restoring near full-length dystrophin. Preclinical data show durable benefit, with IND/CTA filing and initial clinical data expected in 2026.
-
Three programs—hepatitis B, DMD, and OTC deficiency—are advancing, with clinical data expected by late 2026 and strong early safety and efficacy signals. ARCUS technology offers unique gene editing advantages, and the company is well-funded and capital efficient.
-
PBGENE-DMD, a gene editing therapy for DMD, demonstrated durable preclinical efficacy and safety at lower AAV doses, with regulatory alignment for clinical trials in 2026. The approach offers functional dystrophin restoration and long-term muscle improvement, differentiating it from current therapies.
-
Precision BioSciences, at the Needham Healthcare Conference, highlighted its shift to in vivo gene editing with the ARCUS platform. Lead program PBGene-HBV showed early safety/efficacy in chronic hepatitis B; global trials continue with 2025 data expected. The pipeline includes mitochondrial disease and DMD, with strong regulatory progress and cash position.